HomeNVYTF • OTCMKTS
Novacyt SA
$0.54
May 2, 12:19:55 AM GMT-4 · USD · OTCMKTS · Disclaimer
StockUS listed security
Previous close
$0.54
Year range
$0.54 - $1.25
Market cap
31.78M EUR
Avg Volume
3.00
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
(GBP)Dec 2024Y/Y change
Revenue
Operating expense
Net income
Net profit margin
Earnings per share
EBITDA
Effective tax rate
Total assets
Total liabilities
(GBP)Dec 2024Y/Y change
Cash and short-term investments
30.46M-30.87%
Total assets
70.63M-47.22%
Total liabilities
22.75M-51.15%
Total equity
47.88M
Shares outstanding
70.78M
Price to book
0.79
Return on assets
Return on capital
Net change in cash
(GBP)Dec 2024Y/Y change
Net income
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Founded
Jul 3, 2006
Employees
240
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
Search
Clear search
Close search
Google apps
Main menu